5 Undervalued Biotechnology & Medical Research Stocks for Thursday, July 20
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Thursday, July 20 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BiomX Inc., a holding company, focuses on defense, security, and critical infrastructure technologies. The company’s portfolio targets various niches, such as counter-drone systems, AI-enabled command-and-control, perimeter and border security, wide-area surveillance, and aerial firefighting. It serves defense agencies, prime contractors, transportation operators, municipalities, and critical infrastructure providers. The company was founded in 2015 and is based in Dover, Delaware.
Commentary & Analysis
Is Biomx Inc (PHGE) Stock a Good Investment?
Learn more about Biomx Inc's (PHGE) stock grades for Value, Momentum and Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | PHGE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.9 | $252.6 | 1% |
|
| Shares Out (Mil) | 2.6 | 52.3 | 9% |
|
| Institutional Ownership | 38.9% | 92.1% | 17% |
|
| Float (Mil) | 7.9 | 40.2 | 17% |
|
| Beta | 1.19 | 0.95 | 70% |
|
| Avg Daily Volume (000s) | 1,914 | 455 | 81% |
|
| Price Change (52-week) |
(97.6%) | 52.9% | 2% |
|
| Growth | PHGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (3.8%) | (9.9%) | 35% |
|
| EPS (5yr) | 38.3% | 16.0% | 87 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 51.2% | (15.6%) | 94% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | na | ($5.850) | ($6.010) | |
| Month Ago EPS | na | ($5.850) | ($6.010) | |
| # Rev Up | na | 0 | 0 | |
| # Rev Down | na | 1 | 1 | |
| Three Months Ago EPS | na | ($5.850) | ($12.980) | |
| Year/Year Chg | na | (73.6%) | (79.4%) | |
| Financials | PHGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($48) | ($43) | 16% |
|
| EPS (TTM) | ($24.148) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($20) | $5 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $25 | $180 | 12% |
|
| Valuation | PHGE | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PHGE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (195.0%) | (49.8%) | 2% |
|
| ROE | 698.9% | (55.5%) | 100% |
|
| Liabilities to Assets | 127.1% | 30.3% | 97% |
|
| F-Score | 2 | 3 | na |
|
BiomX Inc. did not pass any screens on 7/31/2026.
